Royalty Report: Medical, Supply, Wound Care – Collection: 372627

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Medical
  • Supply
  • Wound Care
  • Drugs
  • Device
  • Nerve
  • cell therapy
  • Tissue
  • Surgical
  • Biotechnology
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372627

License Grant
By the 2003 agreement, Licensor granted an exclusive worldwide sublicense for the Licensed Technology in the Field of Use and the Field of Extended Use.  This amended and restated agreement is to continue the Exclusive Sublicense with the amendments.

Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.

For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.

License Property
Licensed Products means any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins and in combination with a synthetic or natural matrix, or any part thereof i.e., any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins without a matrix, or a synthetic or natural matrix alone, that is covered by the Licensed Patents; is developed through the use of a process that is covered by the Licensed Patents or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Patents.

Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.

Field of Use
GEM 21S was approved by the U.S. Food and Drug Administration the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease.

GEM 21S® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.

GEM 21S® growth-factor enhanced matrix combines a bioactive protein – highly purified rhPDGF-BB – with an osteoconductive matrix, ß-TCP.

GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranio• maxillofacial osseous defects.

The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.

IPSCIO Record ID: 227278

License Grant
University hereby grants to Licensee in the territory and in the field an exclusive commercial license under University patent rights, to make and have made, to use and have used, to sell and have sold the licensed products, and to practice the licensed processes, for the life of the university patent rights. Such licenses shall include the right to grant sublicenses.
License Property
Universitys rights in the United States Patents listed below, and the inventions described and claimed therein
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.

Field of Use
rhPDGF is a key stimulator of the body's natural wound healing process. It has a well-established mechanism of action that leads to stimulation of certain cell types, including those important to bone, cartilage, tendon and ligament healing.

IPSCIO Record ID: 372628

License Grant
These Parties have entered into a certain Asset Purchase Agreement.

For the License, Licensor grants a worldwide license under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products, solely within the Field of Use.

For the Right to Grant Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products within the Field of Use.

License Property
The patents include
Platelet-Derived Growth Factor Compositions and Methods of Use Thereof;
Maxillofacial Bone Augmentation Using rhPDGF-BB and a Biocompatible Matrix;
Compositions and Methods for Repairing Cartilage Defects;
Compositions and Methods for Treating Bone;
Prevention and Treatment for Osteonecrosis and Osteonecrosis of the Jaw;
Methods and Compositions for Treating the Vertebral Column; and,
Compositions and Methods for Treating Rotator Cuff Injuries.

Licensor has certain assets related to the orofacial therapeutic business.

rhPDGF means recombinant human platelet derived growth factor.

Licensed Products means any product with application within the Field of Use that Licensor and/or Licensee develops or has developed which is covered by the Licensed Technology, developed through the use of a process which is covered by the Licensed Technology, or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Technology, including, but not limited to
—  any Growth Factor product, including GEM 21S, GEM ONJ, GEM 22A, and a GEM OS2-like product for application within the Field of Use, including Growth Factors alone, combinations of Growth Factors, and combinations of Growth Factors with non-Growth Factor products, and any component thereof, for which commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement;
—  any device, e.g., bone matrix material, implant and/or related product, for which the commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement.

Field of Use
The Field of Use means all applications above the neck in humans and all veterinary applications. For the avoidance of doubt, Field of Use in humans does not include central nervous system diseases such as multiple sclerosis, nerve regeneration or extraoral dermal or epidermal tissue, except that oral indications, such as cleft lip and palate, that traverse the intraoral-extraoral boundary, are not excluded.

IPSCIO Record ID: 27675

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications. In January 2014, Licensee received 510k approval for their first product under the license, a bioactive bone graft putty and bone graft extender.  In February 2014, Licensor granted a Commercial License to Licensee according to the terms of the development and license agreement.
License Property
The Licensor acquired patent 7,074,425 in September 2009.  It is for a resorbable bone wax and delivery system for orthopedic bone void fillers. The patent offers innovative, safe and effective resorbable orthopedic products that are complementary to the already existing Licensor products.  The bone wax and delivery system address issues such as bone wax granuloma and the cost-effective delivery of materials that manage bone wound healing. The resorbable orthopedic products covered by the patent are (a) a resorbable orthopedic hemostat (resorbable bone wax) used to stop blood flow, (b) a delivery system for osteogenic/osteoinductive orthopedic products (bone void fillers), and (c) the formula as a delivery system for bone growth factors.

IPSCIO Record ID: 5290

License Grant
The Licensee entered into a five-year license agreement with Licensor relative to a technology known as OPLA. The Licensee and Licensor are committed to research and development of specified uses of the OPLA technology.
License Property
The Open-cell Polylactic Acid or OPLA is a porous polymer foam technology, and to our biomaterials technology platform in the orthopedics drug and delivery markets.  This porous tissue matrix technology facilitates wound healing in both bone and soft tissue and is bio absorbable at controlled rates for specific functions and tissues.  This technology adds a series of products, development programs and intellectual property related to porous biodegradable regeneration matrices.  Specifically, we are researching applications for articular cartilage regeneration, bone growth scaffolds for spinal and trauma applications and for the delivery of drugs and growth factors.

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938 A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 226071

License Grant
The Company assumed an exclusive license agreement with an undisclosed Licensee for bioactive bone graft putty.
License Property
Bioactive bone graft putty is an FDA cleared bioactive synthetic bone graft substitute comprised of a mixture of calcium phosphate granules and bioglass granules suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components to fill spaces of missing bone. The product is indicated as a bone void filler for standalone use in posterolateral spine fusion procedures without the aid of autologous extenders or enhancers to meet the needs of the surgeon and effectively facilitate structural fusion of the spine. The ratio of certain components in Signafuse’s composition is similar to ratios found to promote attachment and bone formation to produce a stable scaffold that allows sustained bioactivity and osteoconductivity during the healing process. The patented bioactive component is designed for a faster rate of bone fill than bioglass particles with a broader size range. In vitro studies have demonstrated the product’s effective phosphate layer formation on the surface of the implant as early as seven days after application.

IPSCIO Record ID: 353934

License Grant
Licensed Patents License Licensor hereby grants to Licensee during the Term a nontransferable, nonsublicensable, exclusive right and license under the Licensed Patents in the Field of Use to make, use, offer to sell, sell, and import Licensed Products in the Territory.

Know-How License Licensor hereby grants to Licensee during the Term a nontransferable, nonsublicensable, exclusive right and license in the Field of Use under the Licensed Know-How to make, use, offer to sell, sell, and import Licensed Products.

Licensee hereby grants to Licensor a non-exclusive, nonsublicensable, nontransferable, worldwide, royalty-free, license to all Improvements for use by Licensor to make, use, sell, offer for sale and/or import Licensors products solely outside the Field of Use.

License Property
US Patent Applications
1 – METHODS OF DECELLULARIZING BONE Utility – NPREG
United States of America
Issued
13/787,625
2 – U.S. Provisional Patent Application entitled FISTULA FILLER AND DEPLOYMENT SYSTEM, Application No. 62/684,426; Filing Date June 13, 2018, U.S. PROVISIONAL CONVERSION/ PARIS CONVENTION DEADLINE JUNE 13, 2019
3 – U.S. Provisional Patent Application entitled IMPROVED DECELLULARIZATION OF ISOLATED ORGANS, Application No. 62/821,620
4 – U.S. Provisional Patent Application entitled NON-DESTRUCTIVE METHOD OF DEHYDRATION OF EXTRACELLULAR MATRIX OF DECELLULARIZED ORGANS AND PARTICLES FORMED THEREFROM, Application No. 62/789,218

Miromeshâ„¢ and MirodermTM products
and the following products in development or previously considered
Tendon Wrap
Wound Particulate
Nerve Wrap
Void Filler
Fistula

Miromesh is a biological mesh made using perfusion decelluarized porcine liver for hernia repair applications. It is designed to be implanted to boost soft tissue.

MiroDerm® is a non-crosslinked acellular wound matrix, derived from the highly vascularized porcine liver. It is intended for the management of wounds, including partial and full-thickness wounds; pressure ulcers; chronic vascular ulcers; diabetic ulcers; tunneled, undermined wounds; trauma wounds; drainage wounds; and surgical wounds.

Field of Use
Field of Use means acellular extracellular matrix products derived from perfusion decellularization but excluding (i) decellularized Whole Organs; (ii) all non-clinical applications; and (iii) use in three-dimensional printing applications including but not limited to mapping associated therewith. For the avoidance of doubt, under no circumstances does the Field of Use include the addition of cells to the extracellular matrix.

IPSCIO Record ID: 287764

License Grant
Under the terms of this agreement, the Company recognizes royalty revenue on sales of products containing the Companys patented resorbable bone hemostasis.
License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
Field of Use
Licensed refers to certain bone wax rights to Licensee to develop products in the field of bone remodeling, based on Resorbable’s patent number 7,074,425 (see Note 9 “Intangible Assets”) for use in the human skeletal system.

The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 26284

License Grant
The University granted an exclusive license to several of its patents covering, among other things, enhanced Nell-1 bone mineralization. Under the license, the Licensee is permitted to make, have made, use, sell, offer for sale and import any products covered by the licensed patents in a certain field of use.
License Property
The Licensee is targeting spinal fusion as the first clinical indication and is currently in the pre-investigational device exemption (IDE) phase. The lead product, purified Nell-1 recombinant protein, is expected to be dried onto ß-tricalcium phosphate (TC”) bone void filler to produce a medical device, known as Nell-1/TCP (Nell/TCP Fusion Device). This device will be mixed with 510(k) cleared DBX® Demineralized Bone Putty recommended for use in conjunction with a cleared intervertebral body fusion device. The Nell-1/TCP Fusion Device is intended for use in lumbar spinal fusion and may have a variety of other applications such as cervical spinal fusion.
Field of Use
By a subsequent Seventh Amendment entered into on August 7, 2012, the parties modified the applicable field of use that Licensee is permitted to use the patents in, which generally comprises musculoskeletal repair and regeneration, plus some related methods of manufacture. The Nell-1/TCP Fusion Device will be comprised of a single dose vial of NELL-1 recombinant protein freeze dried onto TCP. A vial of Nell-1/TCP will be sold in a convenience kit with a diluent and a syringe of 510(k) cleared demineralized bone (“DBX® Putty”), produced by MTF. A delivery device will allow the surgeon to mix the reconstituted Nell 1/TCP with the appropriate quantity of DBX® Putty just prior to implantation.

IPSCIO Record ID: 1232

License Grant
The Company entered into a new License Agreement with the Licensors. The Company's exclusive license to use the technology was expanded to include the wound care field, the abdominal and thoracic (general surgery) field, and the breast field. Also in connection with the aforementioned new License Agreement, three other people received cash payments. Two of these individuals are founders of the Company; one of them is also a member of the Board of Directors and the other is an officer of the Company.
License Property
The Licensor of the Company's patented stabilization and sterilization technologies, is a shareholder of the Company, has a member of its management as a member of the Company's Board of Directors, earns a royalty on the Company's net sales of products derived from the licensed technology, and also receives a monthly consulting fee.  The Company holds rights to patented technologies for the stabilization (crosslinking) and sterilization of biological tissue which has enabled development of acellular collagen biomaterials suitable for use as wound dressings as well as for human implantation as ligament, tendon, and soft tissue repair/reinforcement patches or grafts.
Field of Use
The rights granted relate to use the technology was expanded to include the wound care field, the abdominal and thoracic (general surgery) field, and the breast field.

IPSCIO Record ID: 245908

License Grant
Licensor grants to Licensee the worldwide right and exclusive license under the Patent Rights, and the worldwide rights and non-exclusive license under any and all Know-How but only, to make, have made, use, lease, offer for sale, sell, have sold, and import the Licensed Products in the Field of Use.
License Property
The product  Osteolntegrin is Osseointegrative implant coating technology.  The product OsteoMorphin  is Osseoinductive device for bone augmentation and regeneration. And, the product One-Stop-Implant is Moldable osseoinductive matrix that will allow implants to be placed at the time of tooth extraction and will immediately stabilize them in position.

The patents are for Use of Non•lmmunogenic Cartilage and Bone Suspension as Bulking Agents,  Novel Osteopontin Derived Chemotactic Peptides and Methods of Use,  Methods and Compositions for Programming an Organic Matrix for Remodeling into a Target Tissue,  and, Osseointegration into Osteopontin and Hyaluronic Acid Coated Surfaces.

The Licensed Product shall mean any product and/or Licensed Process for the manufacture, development, use, lease, sale or import of which would infringe any one of the issued, unexpired claim(s) or any one of the pending claim(s) contained in the Patent Rights in any country, and/or the manufacture of which uses a Licensed Process.

Licensed Process shall mean any process that would infringe any one of the issued, unexpired claim(s) or any one of the pending claim(s) contained in the Patent Rights in any country.

Field of Use
The Field of Use shall mean, for the Licensed Product Osteolntegrin is Titanium implants for use in oral cavity in humans and animals.

The Field of Use shall mean, for the Licensed Product OsteoMorphin is Dentistry and Periodontics in humans, and, Orthopedic use in humans, and Therapeutic use in animals.

The Field of Use shall mean, for the Licensed Product, One-Stop-Implant  for Therapeutic use in the oral cavity in humans and animals.

IPSCIO Record ID: 3101

License Grant
The Licensee has entered into multiple license agreements with three Universities.  Under the terms of the License Agreements, the Licensee acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves.

The licensed technologies include the rights to issued patents and patents pending in the United States and international markets.

License Property
Avance® Nerve Graft is a human tissue for transplantation.  Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect.

The AxoGuard® Nerve Protector is indicated for the repair of peripheral nerve injuries where there is no gap. The device is supplied sterile and is intended for one-time use.

Field of Use
The Licnesee is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration.

In order to improve surgical reconstruction and regeneration of peripheral nerves, the Licensee has developed and licensed technologies, which are used in its products. Its product portfolio includes Avance® Nerve Graft which the Licensee believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, an implant that protects nerves during the body's healing process after surgery.

IPSCIO Record ID: 5492

License Grant
LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED FIELD and LICENSED TERRITORY, a license under PATENTS, to fully practice PATENTS, including the right to make, use, offer for sale, sell and import PRODUCTS and promote the methods and compositions recited in the claims of PATENTS using PRODUCTS in the LICENSED FIELD.
License Property
The U.S. and foreign issued patents relates to platelet-based growth factors (used in platelet rich plasma gel used in wound care in the specific field of use covering diagnostic and therapeutic spinal, neurosurgery and orthopedic surgery. U.S. Patent No. 5,165,938 entitled “Wound Healing Agents,” issued 11/24/92.
Field of Use
SCHEDULE OF PRODUCTS
SEPARATORS
2760-40-101       Disposable Processing Kit – Single
2760-40-102       Disposable Processing Kit – Double

Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge

CAPITAL
2760-40-000       Centrifuge
2760-40-310       Centrifuge and Cart Assembly

APPLICATORS/ MIXERS
2760-40-200       Applicator Kit

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.